Decision Makers
| Name (plus bio) |
Position |
| Robert E. Conway |
Chief Executive Officer |
| Douglas E. Williams |
President, Zymogenetics |
| Kevin Koch |
President & Chief Scientific Officer |
| David L. Snitman |
Chief Operating Officer & Vice President, Business Development |
| R. Michael Carruthers |
Chief Financial Officer |
| Yates John |
Chief Medical Officer |
| April H. Teitelbaum |
Vice President, Clinical Dev, Oncology |
| Gary M. Clark |
Vice President, Biostatistics & Data Mgmt |
| James D. Winkler |
Vice President, Discovery & Translational Biology |
| John A. Josey |
Vice President, Discovery Chemistry |
| John Moore |
Vice President & General Counsel |
| Gregory L Huckabee |
Director, Operations |
| James P. Rizzi |
Director, Computational Technology |
| Laurence Burgess |
Senior Director, Medicinal Chemistry & Lead Optimization |
| Patrice Lee |
Director, Pharmacology & Toxicology |
| Patricia Lee |
Director, Pharmacology & Toxicology |
| Ronald B. Franklin |
Senior Director, Drug Metabolism |
| Sherri Norland |
Director, Hr |
| Steven A. Boyd |
Director, Medicinal Chemistry |
| Marvin H. Caruthers |
Distinguished Professor of Biochemistry and Bioorganic Chemistry |
| Randall K Johnson |
Independent Consultant |
| S Gail Eckhardt |
Professor of Medicine at the University of Colorado Health Sciences Center |
| Joseph P. Lyssikatos |
Director |
Board of Directors
Robert E. Conway has agreed to serve as a director on our board upon completion of this offering. Mr. Conway is currently the chief executive officer of Array BioPharma Inc., which he joined in November 1999. Prior to joining Array BioPharma, Mr. Conway was the chief operating officer and executive vice president of the Clinical Trials Division of Hill Top Research, Inc., which he joined in 1996. Mr. Conway serves on the boards of directors of Array BioPharma and DEMCO, Inc. Mr. Conway received a B.S. in accounting from Marquette University and an M.B.A. from the University of Cincinnati, and is a Certified Public Accountant.
| Organization |
Position |
Status |
| Array BioPharma, Inc. |
Chief Executive Officer |
Current |
| Genstar Capital LLC |
Board of Directors |
Current |
| Array BioPharma, Inc. |
Board of Directors |
Current |
| Wall Family Enterprise |
Director |
Current |
| PRA International Inc. |
Board of Directors |
Current |
| Cromedica |
Director |
Current |
| Computer Review |
Chief Executive Officer |
Former |
| Hill Top Research Inc. |
Chief Operating Officer |
Former |
| Hill Top Research Inc. |
Executive Vice President |
Former |
| University of Cincinnati |
M.B.A |
Former |
| Marquette University |
B.S. In Accounting |
Former |
Douglas E. Williams, Ph.D., 50, has served as a member of our Board of Directors since April 2004. He currently serves as President of ZymoGenetics, Inc. From September 2003 to August 2004, Dr. Williams served as Seattle Genetics' Chief Scientific Officer, Executive Vice President and a member of their Board of Directors. Prior to joining Seattle Genetics, from November 2002 to August 2003, Dr. Williams was Head of Health and Strategic Development for Genesis Research & Development, a biotechnology company located in New Zealand. From July to October 2002, he served as Senior Vice President, Washington Site Leader and a member of the Executive Committee for Amgen, Inc. Dr. Williams joined Amgen in July 2002 when it acquired Immunex Corporation, where he worked for 14 years, most recently serving as Executive Vice President, Chief Technology Officer and a member of Immunex's Board of Directors. Prior to his work at Immunex, Dr. Williams served on the faculty of the Indiana University School of Medicine and the Department of Laboratory Medicine at the Roswell Park Memorial Institute. He serves on the boards of privately-held Aerovance, Inc. and of publicly traded Anadys Pharmaceuticals, Inc. and is a member of the Scientific Advisory Board of Symphony Capital. Dr. Williams holds a B.S. magna cum laude in Biological Sciences from the University of Massachusetts, Lowell and a Ph.D. in Physiology from the State University of New York at Buffalo, Roswell Park Division.
| Organization |
Position |
Status |
| Array BioPharma, Inc. |
President, Zymogenetics |
Current |
| ZymoGenetics, Inc. |
Chief Scientific Officer |
Current |
| ZymoGenetics, Inc. |
Executive Vice President, Research and Development |
Current |
| Symphony Capital LLC |
Board of Directors |
Current |
| Aerovance, Inc |
Board of Directors |
Current |
| Array BioPharma, Inc. |
Board of Directors |
Current |
| Anadys Pharmaceuticals, Inc. |
Board of Directors |
Current |
| Seattle Genetics, Inc. |
Board of Directors |
Current |
| Genesis Research and Development Corporation Limited |
Board of Directors |
Current |
| ZymoGenetics, Inc. |
Chief Executive Officer |
Former |
| Immunex Corporation |
Chief Technology Officer |
Former |
| Seattle Genetics, Inc. |
Chief Scientific Officer |
Former |
| Immunex Corporation |
Executive Vice President |
Former |
| Seattle Genetics, Inc. |
Executive Vice President, Research and Development |
Former |
| Amgen Inc. |
Senior Vice President |
Former |
| Immunex Corporation |
Senior Vice President of Discovery Research |
Former |
| Genesis Research and Development Corporation Limited |
Head of Health and Strategic Development |
Former |
| Genesis Research |
Head of Health and Strategic Development |
Former |
| Immunex Corporation |
Board of Directors |
Former |
| The State University of New York |
Ph.D. in Physiology |
Former |
| State University of New York at Buffalo |
Ph.D. In Physiology |
Former |
| University of Massachusetts Amherst |
B.S. Magna Cum Laude In Biological Sciences |
Former |
| Immunex Corporation |
Member |
Former |
Kevin Koch, Ph.D., 48, is a Co-Founder of Array and has served as our President, Chief Scientific Officer and a member of our Board of Directors since May 1998. Prior to forming Array, Dr. Koch was an Associate Director of Medicinal Chemistry and Project Leader for the Protease Inhibitor and New Leads project teams for Amgen Inc. from 1995 to 1998. From 1988 until 1995, Dr. Koch held various positions with Pfizer Central Research, including Senior Research Investigator and Project Coordinator for the Cellular Migration and Immunology Project Teams. From 1998 to 2003, Dr. Koch was an elected board member of the Inflammation Research Association. Dr. Koch received a B.S. in chemistry and biochemistry from the State University of New York at Stony Brook and a Ph.D. in synthetic organic chemistry from the University of Rochester.
| Organization |
Position |
Status |
| Array BioPharma, Inc. |
President & Chief Scientific Officer |
Current |
| Array BioPharma, Inc. |
Founder |
Current |
| Array BioPharma, Inc. |
Board of Directors |
Current |
| Amgen Inc. |
Associate Director |
Former |
| Amgen Inc. |
Project Leader |
Former |
| Pfizer Inc. |
Project Coordinator |
Former |
| Inflammation Research Association |
Board Member |
Former |
| University of Rochester |
Ph.D. In Synthetic Organic Chemistry |
Former |
| State University of New York at Stony Brook |
B.S. in chemistry and biochemistry |
Former |
David L. Snitman, Ph.D., 55, is a Co-Founder of Array and has served as our Chief Operating Officer, our Vice President of Business Development and a member of our Board of Directors since May 1998. Prior to forming Array, Dr. Snitman held various positions with Amgen Inc. since December 1981, including Associate Director, New Products and Technology and Manager of Amgen s Boulder research facility. Dr. Snitman currently serves on the Board of Directors of Barofold Inc. Dr. Snitman received a B.S. in chemistry from Northeastern University and a Ph.D. in the synthesis of natural products from the University of Colorado, and was a National Institutes of Health Postdoctoral Fellow at the Massachusetts Institute of Technology.
| Organization |
Position |
Status |
| Array BioPharma, Inc. |
Chief Operating Officer & Vice President, Business Development |
Current |
| Array BioPharma, Inc. |
Co-Founder |
Current |
| Array BioPharma, Inc. |
Director |
Current |
| Barofold, Inc |
Board of Directors |
Current |
| Amgen Inc. |
Associate Director, New Products and Technology |
Former |
| Amgen Inc. |
Manager |
Former |
| University of Colorado |
Ph.D. |
Former |
| Northeastern University |
B.S. In Chemistry |
Former |
| Organization |
Position |
Status |
| Array BioPharma, Inc. |
Chief Financial Officer |
Current |
| Pyxant Labs Inc |
Board of Directors |
Current |
| Dover Corporation |
Controller |
Former |
| Dover Corporation |
Treasurer |
Former |
| University of Chicago |
M.B.A |
Former |
| University of Colorado |
B.S. In Accounting |
Former |
| Organization |
Position |
Status |
| Array BioPharma, Inc. |
Chief Medical Officer |
Current |
| Organization |
Position |
Status |
| Array BioPharma, Inc. |
Vice President, Clinical Dev, Oncology |
Current |
| Organization |
Position |
Status |
| Array BioPharma, Inc. |
Vice President, Biostatistics & Data Mgmt |
Current |
| American Chamber of Commerce |
Board of Directors |
Current |
| American Institute of Certified Public Accountants |
Board of Directors |
Current |
| Shui On Land Limited |
Board of Directors |
Current |
| American Chamber of Commerce |
Member |
Current |
| American Institute of Certified Public Accountants |
Member |
Current |
| University of Washington |
Professor |
Former |
| Breast Center |
Board of Directors |
Former |
| Organization |
Position |
Status |
| Array BioPharma, Inc. |
Vice President, Discovery & Translational Biology |
Current |
| Array BioPharma, Inc. |
Senior Director, Discovery Biology |
Former |
| Array BioPharma, Inc. |
Director |
Former |
| Medical College of Pennsylvania |
Ph.D. In Pharmacology |
Former |
| Princeton University |
B.A. In Biochemistry |
Former |
Dr. Josey has served as Vice President of Discovery Chemistry since September 2004. From May 1998 to August 2004, Dr. Josey was the Senior Director of Lead Generation. Prior to joining Array, Dr. Josey had been employed by Amgen Inc. since 1995 in the New Leads/Combinatorial Chemistry Group of Amgen's small molecule drug discovery program. From 1991 until 1995, Dr. Josey was a Research Investigator in the Medicinal Chemistry Department at the Glaxo Research Institute. Dr. Josey received a B.S. degree in chemistry from Colorado State University, a Ph.D. degree in organic chemistry from The University of Texas at Austin, and was a Damon Runyon-Walter Winchell Postdoctoral Fellow at the California Institute of Technology.
| Organization |
Position |
Status |
| Array BioPharma, Inc. |
Vice President, Discovery Chemistry |
Current |
| Amgen Inc. |
Investigator Medicinal Chemistry Department |
Former |
| The Lead Generation Limited |
Board of Directors |
Former |
| The University of Texas at Austin |
Ph.D. Degree In Organic Chemistry |
Former |
| Colorado State University |
B.S. Degree In Chemistry |
Former |
John is the Chairman and CEO of the Marwood Group, a healthcare investment and financial services firm. John is a graduate of the University of North Carolina at Chapel Hill. John is married and lives with his wife Tanya, their daughter, Alexandra and son John Jr. in New York.
| Organization |
Position |
Status |
| Marwood Group LLC |
CEO |
Current |
| Computer Review |
Vice President & General Counsel |
Current |
| Array BioPharma, Inc. |
Vice President & General Counsel |
Current |
| The Metropolitan Foundation |
|
Current |
| Marwood Group LLC |
Chairman |
Current |
| Computer Review |
Secretary |
Current |
| Array BioPharma, Inc. |
Secretary |
Current |
| Kenyon & Kenyon Llp |
Associate |
Former |
| Wilson Sonsini Goodrich & Rosati |
associate |
Former |
| The University of North Carolina at Chapel Hill |
J.D. |
Former |
| University of Illinois |
M.S. In Biochemistry |
Former |
| University of Illinois at Urbana-Champaign |
M.S. In Biochemistry |
Former |
| The University of North Carolina at Chapel Hill |
B.S. In Chemistry |
Former |
| Organization |
Position |
Status |
| Array BioPharma, Inc. |
Director, Operations |
Current |
| Botanical Laboratories, Inc. |
Director of Operations |
Former |
| Hauser, Inc. |
Manager of Strategic Resources |
Former |
| Array BioPharma, Inc. |
Manager of Operations |
Former |
Dr. Rizzi has served as Director of Computational Technology since February 2001. Prior to joining Array, Dr. Rizzi served as Senior Director of Business Development for Tripos Inc. from 1999 to 2001. Dr. Rizzi was Head of Chemistry and Structural Biology for Source Pharmaceuticals from 1998 to 1999 and was a Lab Head at Amgen, Boulder in charge of computational chemistry from 1995 to 1998. From 1981 to 1995 Dr. Rizzi was at Pfizer Central Research where his early career focused on medicinal chemistry in the fields of diabetes and immunology. In 1989, he joined the computational chemistry group at Pfizer. His responsibilities included support of the CNS, inflammation, immunology, and infectious disease areas. Dr. Rizzi received his B.S. degree in chemistry from Hofstra University and a Ph.D. in synthetic chemistry from the University of Rochester.
| Organization |
Position |
Status |
| Array BioPharma, Inc. |
Director, Computational Technology |
Current |
| Array BioPharma, Inc. |
Director |
Current |
| Tripos Inc. |
Senior Director of Business Development |
Former |
| Amgen Inc. |
Lab Head |
Former |
| Pfizer Inc. |
|
Former |
| University of Rochester |
Ph.D. In Synthetic Chemistry |
Former |
| Hofstra University |
B.S. Degree In Chemistry |
Former |
| Organization |
Position |
Status |
| Array BioPharma, Inc. |
Senior Director, Medicinal Chemistry & Lead Optimization |
Current |
| Amgen Inc. |
|
Former |
| The University of Texas |
Ph.D. |
Former |
| Georgia Institute of Technology |
B.S. in chemistry |
Former |
| Organization |
Position |
Status |
| Array BioPharma, Inc. |
Director, Pharmacology & Toxicology |
Current |
| Array BioPharma, Inc. |
Director |
Current |
| Amgen Inc. |
|
Former |
| Ribozyme Pharmaceuticals Inc |
Director |
Former |
| Duke University |
Ph.D. In Physiology and Toxicology |
Former |
| University of Miami |
B.S. In Biology, Marine Science |
Former |
| Organization |
Position |
Status |
| Array BioPharma, Inc. |
Director, Pharmacology & Toxicology |
Current |
| Array BioPharma, Inc. |
Director, Pharmacology & Toxicology |
Former |
| Organization |
Position |
Status |
| Array BioPharma, Inc. |
Senior Director, Drug Metabolism |
Current |
| Array BioPharma, Inc. |
Senior Director, Drug Metabolism |
Former |
| Eli Lilly and Company |
|
Former |
| Amgen Inc. |
|
Former |
| University of London |
Ph.D. in Biochemistry |
Former |
| Organization |
Position |
Status |
| Array BioPharma, Inc. |
Director, Hr |
Current |
| HealthSouth Corporation |
Facility Manager |
Former |
| Array BioPharma, Inc. |
Manager of Human Resources |
Former |
| HealthSouth Corporation |
Coordinator |
Former |
| Boulder Community Hospital |
Coordinator |
Former |
| Colorado State University |
Masters Degree In Human Resources Development |
Former |
| Concordia College |
B.A. In Business Administration |
Former |
Dr. Boyd has served as Director of Medicinal Chemistry since October 2000. Prior to joining Array, Dr. Boyd was Senior Group Leader in the Pharmaceutical Products Division of Abbott Laboratories, where his research areas included drug discovery in cardiovascular, inflammatory, immunological, and metabolic diseases. Dr. Boyd received a B.A. in chemistry from the University of Oregon Honors College, and a Ph.D. in organic chemistry from the University of California, Los Angeles. He was a National Cancer Institute post-doctoral fellow at the University of Wisconsin.
| Organization |
Position |
Status |
| Array BioPharma, Inc. |
Director, Medicinal Chemistry |
Current |
| Array BioPharma, Inc. |
Director |
Current |
| Abbott Laboratories |
Group Leader Pharmaceutical Products Division |
Former |
| University of Wisconsin |
Fellow |
Former |
| University of California, Los Angeles |
Ph.D. In Organic Chemistry |
Former |
| University of Oregon |
B.A. In Chemistry |
Former |
| Organization |
Position |
Status |
| Boulder Ventures Limited |
Venture Partner |
Current |
| University of Colorado |
Professor of Chemistry |
Current |
| Array BioPharma, Inc. |
Distinguished Professor of Biochemistry and Bioorganic Chemistry |
Current |
| Barofold, Inc |
Board of Directors |
Current |
| Array BioPharma, Inc. |
Board of Directors |
Current |
| National Academy of Sciences |
Board of Directors |
Current |
| Array BioPharma, Inc. |
Investor |
Current |
| American Academy of Arts and Sciences |
Member |
Current |
| National Academy of Sciences |
Member |
Current |
| Amgen Inc. |
Co-founder |
Former |
| Applied Biosystems Group |
Co-founder |
Former |
| Northwestern University |
Ph.D. In Chemistry |
Former |
| Iowa State University |
B.S. In Chemistry |
Former |
| Massachusetts Institute of Technology |
post-doctoral studies |
Former |
Dr. Johnson, with over 30 years of experience in government and industry, has worked in all aspects of cancer drug discovery/development. This experience ranges from target validation, through screening technologies, basic research on mechanisms of drug action, assessment of efficacy in preclinical tumor models, to clinical development plans and regulatory strategies. He has put many drugs into clinical development and is credited with bringing topotecan to market. After receiving a degree in Pharmacology, Dr. Johnson worked at the National Cancer Institute, at Arthur D Little, and for 20 years at GlaxoSmithKline / SmithKline Beecham Pharmaceuticals. He now consults for many pharmaceutical companies, both large and small, provides venture capital groups with assessment of investment opportunities and serves on the Scientific Advisory Boards of five other biotechnology companies.
| Organization |
Position |
Status |
| Array BioPharma, Inc. |
Independent Consultant |
Current |
| Sbio Inc. |
Board of Directors |
Current |
| Combinature Biopharm AG |
Board of Directors |
Current |
| Tetralogic Pharmaceuticals |
Board of Directors |
Current |
| Sapphire Therapeutics, Inc |
Board of Directors |
Current |
| American Association for Cancer Research, Inc. |
Member |
Current |
| Bethesda |
Section Head |
Former |
| National Cancer Institute |
Section Head |
Former |
| Arthur D. Little, Inc. |
|
Former |
| The George Washington University |
Ph.D. In Pharmacology |
Former |
| University of Minnesota |
B.Sc. In Biochemistry |
Former |
| Organization |
Position |
Status |
| Array BioPharma, Inc. |
Professor of Medicine at the University of Colorado Health Sciences Center |
Current |
Dr. Francis Bullock is a Senior Advisor to PureTech Ventures. Previously, he served as the Senior Vice President, Research Operations at Schering Plough Research Institute, from 1981-1993, where he took over 30 new chemical entities into clinical development in many therapeutic areas including antibacterials, antifungals, antivirals, cardiovasculars, pain, inflammation, allergy, and cancer. His track record includes five successful registrations including Claritin and Intron (Interferon Alpha 2b) that generated cumulative peak sales of around $3.5B annually. Dr. Bullock serves on the board of directors for TSI Corporation, Genzyme Transgenics Corporation, Array Biopharma, and ARCA Discovery.
| Organization |
Position |
Status |
| PureTech Ventures |
Partner |
Current |
| Gelesis Inc. |
Advisor |
Current |
| Paintedfrog Studio |
|
Current |
| GTC Biotherapeutics, Inc. |
Board of Directors |
Current |
| ARCA Discovery, Inc. |
Board of Directors |
Current |
| Array BioPharma, Inc. |
Board of Directors |
Current |
| TSI Incorporated |
Director |
Current |
| Genzyme Transgenics Corporation |
Board of Directors |
Current |
| Schering-Plough Research Institute |
Senior Vice President, Research Operations |
Former |
| Arthur D. Little, Inc. |
Senior Consultant |
Former |
| Harvard University |
Ph.D. In Organic Chemistry |
Former |
| Massachusetts College of Pharmacy and Health Sciences |
B.S. In Pharmacy |
Former |
Gil J. Van Lunsen was appointed to the audit committee on March 8, 2005. Van Lunsen was a managing partner of KPMG LLP and led the firm's Tulsa, Oklahoma, office before retiring in June 2000. During his career, Van Lunsen served clients in several industries including energy. He is currently a director and audit committee chairman of Array Biopharma and Sirenza Microdevices. Additionally, Van Lunsen was a member of the ethics compliance committee of Tyson Foods, Inc. and the audit committee chairman and member of the board of directors for Hillcrest Healthcare System.
| Organization |
Position |
Status |
| ONEOK Partners, L.P. |
Member, Board of Directors and Audit Committee |
Current |
| Array BioPharma, Inc. |
Board of Directors |
Current |
| KPMG International |
partner-in-charge |
Former |
| Sirenza Microdevices, Inc. |
Director |
Former |
| Tyson Foods, Inc. |
member |
Former |
| Organization |
Position |
Status |
| PureTech Ventures |
Co-Founder, Senior Partner |
Current |
| Protein Forest, Inc. |
General Partner and Co-Founder of Puretech Ventures |
Current |
| Genstar Capital LLC |
Strategic Advisory Committee Member |
Current |
| Protein Forest, Inc. |
Chairman |
Current |
| The Convergence Forum |
|
Current |
| Momenta.Com |
Board of Directors |
Current |
| Biomira Inc. |
Board of Directors |
Current |
| Harlan Sprague Dawley Inc. |
Director |
Current |
| PureTech Ventures |
Director |
Current |
| Biosource International, Inc. |
Board of Directors |
Current |
| Genstar Capital LLC |
Board of Directors |
Current |
| Array BioPharma, Inc. |
Board of Directors |
Current |
| Cellicon Biotechnologies, Inc. |
Board Members |
Current |
| Protein Forest, Inc. |
Board Members |
Current |
| ARCA Discovery, Inc. |
Board Members |
Current |
| Kellogg Company |
Board of Directors |
Current |
| MacroChem Corporation |
Director |
Current |
| Pharmacia & Upjohn |
CEO |
Former |
| The Upjohn Company |
CEO |
Former |
| Life Science Products, Inc. |
CEO |
Former |
| Pharmacia Corporation |
Chief Executive Officer |
Former |
| Merck Manufacturing Division |
President |
Former |
| Pharmacia Corporation |
President |
Former |
| Life Science Products, Inc. |
President |
Former |
| Pharmacia & Upjohn |
President |
Former |
| Merck & Co. Inc. |
Executive Vice President |
Former |
| Pure Tech Incorporated |
|
Former |
| Life Science Products, Inc. |
Chairman |
Former |
| The Upjohn Company |
Chairman |
Former |
| MacroChem Corporation |
Chair of Board |
Former |
| Momenta Pharmaceuticals, Inc. |
Board Members |
Former |
| Momenta Pharmaceuticals, Inc. |
Founding Investors |
Former |
| University of Rochester |
Ph.D. in organic chemistry |
Former |
| Dartmouth College |
AB in chemistry |
Former |
Dr. Lyssikatos has served as Director of Lead Optimization since May 2003. Before joining Array, Dr. Lyssikatos had been employed by Thios Pharmaceuticals to build and lead their medicinal chemistry and in-vitro pharmacology groups. From 2001 until 2002, Dr. Lyssikatos was employed by Array, most recently serving as Senior Group Leader for the Company's proprietary oncology and inflammation research programs. Prior to joining Array, Dr. Lyssikatos was employed for nine years by Pfizer Inc. focusing on various research areas, including PDGFR inhibitors, Ftase inhibitors, immune stimulants and antibacterials. Dr. Lyssikatos received a B.S. in chemistry from The College of William and Mary and a Ph.D. from The University of California at Berkeley.
| Organization |
Position |
Status |
| Array BioPharma, Inc. |
Director |
Current |
| Array BioPharma, Inc. |
Director, Lead Optimization |
Former |
| Array BioPharma, Inc. |
Group Leader |
Former |
| University of California, Berkeley |
Ph.D. |
Former |
| Organization |
Position |
Status |
| Boulder Ventures Limited |
General Partner |
Current |
| Array BioPharma, Inc. |
Chairman |
Current |
| American Mountain Guide Association |
|
Current |
| Barofold, Inc |
Chairman |
Current |
| ARCA Discovery, Inc. |
Director |
Current |
| Centerstone Technologies, Inc. |
Director |
Current |
| Array BioPharma, Inc. |
Board Member |
Current |
| Lefthand Networks, Inc. |
Director |
Current |
| Trust Company of America |
Director |
Current |
| Boulder Ventures Limited |
Founder |
Former |
| University of Colorado |
Adjunct Professor of Finance |
Former |
| American Expedition |
Board of Directors |
Former |
| University of Chicago |
MBA In Finance |
Former |
| Vassar College |
B.A. In Economics |
Former |
| The London School of Economics |
Fellowship in Economic History |
Former |
| Organization |
Position |
Status |
| Array BioPharma, Inc. |
Board of Directors |
Current |
Executive News
-
Array BioPharma, Inc. (ARRY) to Present at the Jefferies 3rd Annual Healthcare Conference
BioSpace - 6/12/09 - View Story
-
Array BioPharma to Present at the Jefferies 3rd Annual Healthcare Conference
Business Wire - 6/11/09 - View Story
-
ZymoGenetics Appoints Eleanor L. Ramos, M.D. Senior Vice President and Chief Medical Officer
RBC Dain Raushcer - 6/10/09 - View Story
-
ZymoGenetics Appoints Eleanor L. Ramos, M.D. Senior Vice President and Chief Medical Officer
Stockwatch - 6/10/09 - View Story
-
ZymoGenetics Appoints Eleanor L. Ramos, M.D. Senior Vice
Business Wire via MSN Money - 6/10/09 - View Story
-
ZymoGenetics Appoints Eleanor L. Ramos, M.D. Senior Vice President and Chief Medical Officer
Business Wire - 6/10/09 - View Story
-
Array BioPharma Schedules Date to Report Financial Results for the Third Quarter of Fiscal 2009
TMC Net - 5/29/09 - View Story
-
Array BioPharma Receives Additional $40 Million Funding Commitment
Reuters - 5/19/09 - View Story
-
Array BioPharma Receives Additional $40 Million Funding Commitment
RBC Dain Raushcer - 5/19/09 - View Story
-
Array BioPharma Receives Additional $40 Million Funding Commitment
Business Wire - 5/19/09 - View Story